

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (original): A retrovirus vector that is capable of transducing cells in a G₀ phase, whereby the vector is derived from a SIVsmmPBj14 virus.

Claim 2 (original): The retroviral vector according to claim 1, whereby the vector is further capable of transducing cells in a mitotic phase and/or a G₁ phase.

Claim 3 (currently amended): The retroviral vector according to claim 1, ~~claim 1 or 2~~; whereby part of or the entirety of a SIVsmmPBj14 *env* gene is deleted.

Claim 4 (original): The retroviral vector according to claim 3, whereby the deletion of the SIVsmmPBj14 *env* gene is in the SU range.

Claim 5 (currently amended): The retroviral vector according to claim 1, any of claims 1 to 4; whereby the vector is a pseudotype vector.

Claim 6 (currently amended): The retroviral vector according to claim 1, any of claims 1 to 5; comprising a part of or the entirety of an envelope protein of a virus other than the SIVsmmPBj14 virus.

Claim 7 (original): The retroviral vector according to claim 6, whereby the virus is selected from HIV-1, SIVagm, SNV, MLV or VSV.

Claim 8 (original): The retroviral vector according to claim 6, whereby the envelope protein is the G-protein of VSV.

Claim 9 (original): A method for making pseudotype vectors, comprising the steps of:

- a) deleting a part of or the entire *env* gene of a SIVsmmPBj14 virus or a molecular clone thereof; and
- b) cotransfected cells with the construct of a) and an expression construct for an envelope protein, whereby the envelope protein is derived from a virus other than the SIVsmmPBj14 virus.

Claim 10 (original): The method according to claim 9, whereby deleting the *env* gene renders the envelope protein nonfunctional.

Claim 11 (currently amended): The method according to claim 9, claim 9 or 10; whereby the cells are 293T cells.

Claim 12 (currently amended): The method according to claim 9, any of claims 9 to 11, whereby the virus is selected from HIV-1, SIVagm, SNV, MLV or VSV.

Claim 13 (currently amended): The method according to claim 9, any of claims 9 to 11, whereby the envelope protein is the G-protein of VSV.

Claim 14 (currently amended): A pseudotype vector according to the method of claim 9 any of claims 9 to 13.

Claim 15 (currently amended): Use of a vector according to claim 9 any of claims 1 to 8 or 14 for transducing cells in the G_0 phase.

Claim 16 (original): Use according to claim 15, whereby the mammalian cells are human lymphocytes.

Claim 17 (currently amended): Use according to claim 15, claim 15 or 16, whereby the cells in the G_0 phase are activated or nonactivated.